Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Teva Pharmaceutical sees weaker than expected 2019

Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.

Read More »

Agenda 2019 Special Feature: Hungry AIs

Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

Neurogene Launches to Advance Gene Therapies

New York-based Neurogene raised $68.5 million in a Series A funding round to support the company’s pipeline of therapeutics aimed at rare neurological diseases.

Read More »

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch after the firm’s attempt to stay a U.S. District court judgement was rejected.

Read More »

Gilead misses key goal in NASH liver disease trial, shares sink

Gilead Sciences Inc. said a late-stage study for selonsertib aimed at treating the progressive fatty liver disease NASH failed to meet the key experimental drug’s main goal, sending the company’s shares down 4.6 percent.

Read More »

IFM Therapeutics Launches New Subsidiary Aimed at Parkinson’s and NASH

IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.

Read More »

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

AbbVie Inc., along with Teneobio Inc. and that company’s affiliate TeneoOne Inc., announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

Read More »

Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

Samsung Bioepis Co. Ltd. announced the company’s expansion in mainland China through a licensing agreement with C-Bridge Capital. The transaction covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12 – which reference Lucentis (ranibizumab) and Soliris (eculizumab) – as well as the biosimilar candidate SB3 that references Herceptin (trastuzumab).

Read More »

Gossamer Bio Wins Big with $276 Million IPO

After struggling with IPO launches during the U.S. government shutdown, Gossamer Bio got on the market and raised $276 million, exceeding expectations.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom